scPharmaceuticals (NASDAQ:SCPH) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

scPharmaceuticals (NASDAQ:SCPH) posted its earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.05, Zacks reports. The firm had revenue of $12.15 million during the quarter, compared to analysts’ expectations of $12.08 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%.

scPharmaceuticals Trading Down 0.3 %

SCPH opened at $3.04 on Thursday. The firm has a market cap of $152.12 million, a price-to-earnings ratio of -1.60 and a beta of 0.40. scPharmaceuticals has a 52 week low of $2.75 and a 52 week high of $5.70. The business’s 50 day moving average is $3.30 and its two-hundred day moving average is $3.81. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research note on Monday, March 3rd.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.